Start here if you're new
what it is
Stryker sells the implants, surgical tools, and neuro equipment hospitals buy and then keep using for years.
how it gets paid
Last year Stryker made $25.1B in revenue.
why it's growing
Revenue grew 250.2% last year. The michigan-based company is a fairly good investment play on growing healthcare demand within the united states.
what just happened
Stryker just posted $7.2B in quarterly revenue, up 11% vs. prior year, while the last reported quarter also beat estimates.
At a glance
A balance sheet — strong enough to weather a downturn
95/100 earnings predictability — you can trust these numbers
26.3x trailing p/e — priced about right
1.0% dividend yield — cash in your pocket every quarter
16.0% return on capital — nothing to write home about
xvary composite: 74/100 — average
What they do
Stryker sells the implants, surgical tools, and neuro equipment hospitals buy and then keep using for years.
Hospitals do not swap implant systems or operating room equipment just to save a little money. Surgeons train on one workflow, staff learns one setup, and service contracts pile on. That switching cost (hard to replace without pain) shows up in a 29.0% operating margin and 95 earnings predictability.
How they make money
$25.1B
annual revenue · their business grew +250.2% last year
total revenue
$25.1B
+250.2%
The products that matter
joint implants and orthopaedic hardware
Orthopaedics
part of a $25.1B revenue base
this sits inside a company that grew 11.2% last year. The demand driver is simple: hips, knees, and trauma cases do not care what the market multiple is doing.
procedure-driven
surgical equipment and hospital tools
MedSurg
supported by strong hospital spending
recent equipment spending by hospitals and health systems was fairly strong. In a business with a 21.3% net margin, utilization and replacement cycles matter more than headlines.
hospital spend
higher-acuity device portfolio
Neurotechnology & Spine
backs the 95 / 100 predictability score
management pointed to healthy procedure counts heading into late 2025. Segment-level revenue is thin in this snapshot, but the message is clear: breadth helps smooth the earnings line.
mix support
Key numbers
29.0%
operating margin
Operating margin → what is left after running the business → so what: Stryker keeps almost $0.29 from every sales dollar before interest and taxes.
16.0%
return on capital
Return on capital → profit earned on the money tied up in the business → so what: this is well above average and says management is not wasting assets.
$14.8B
long-term debt
Long-term debt → money owed over many years → so what: the load is big in dollars but only 10% of capital, which keeps it manageable.
95
predictability score
Earnings predictability → how steady profits have been over time → so what: this is a very consistent business, which is why investors pay up for it.
Financial health
A
strength
- balance sheet grade A — very strong financial position
- risk rank 2 — safer than 80% of stocks
- price stability 85 / 100
- long-term debt $14.8B (10% of capital)
- net profit margin 22.0% — keeps 22 cents of every dollar in revenue
- return on equity 21% — $0.21 profit for every $1 investors have put in
A with balance sheet grade and risk rank standing out. your money faces less risk here than at most public companies.
Total return vs. market
You invested $10,000 in SYK 3 years ago → it's now worth $14,560.
The index would have given you $14,770.
source: institutional data · total return
What just happened
beat estimates
Stryker just posted $7.2B in quarterly revenue, up 11% vs. prior year, while the last reported quarter also beat estimates.
Revenue rose to $7.2B and EPS came in at $2.20, up 56% vs. prior year, with gross margin at 64.5%. The reported quarter also beat consensus at $4.47 versus $4.39 expected.
$7.2B
revenue
$2.20
eps
64.5%
gross margin
the number that mattered
The 64.5% gross margin matters most because it shows Stryker still has pricing power even while hospitals watch budgets.
-
management slightly raised its full-year 2025 outlook for stryker corp. in late october.
-
leadership said that it sees the medical technology giant earning at least $13.50 a share on an adjusted basis, up 11% from 2024’s $12.19 tally and modestly above its previous baseline target of $13.40.
-
in a best-case scenario, share profit was still seen rising just under 12%, to $13.60, on top of the previous year’s 15% bottom-line advance. (note: the company was slated to release full-year 2025 results shortly after we went to press.) the market backdrop seemed generally favorable heading into 2026.to wit, the overall number of surgical procedures incorporating stryker’s technology was expected to remain healthy in the final few months of 2025.
-
moreover, equipment spending by hospitals and health systems was recently fairly robust.the michigan-based company is a fairly good investment play on growing healthcare demand within the united states. there are over 70 million members of the baby boomer generation in the u.s., the youngest of whom are now turning 61 years old. this graying of america augurs well for everything from age-related hip and knee replacement to generally noninvasive surgical procedures like (venous clot-removing) mechanical thrombectomy. against that backdrop, we look for stryker’s earnings to reach $21.85 a share over the next three to five years.
-
acquisitions are a major part of stryker’s playbook.over the past decade, the company has completed in excess of 60 deals with likely more to come, according to management., it wouldn’t surprise us if stryker aimed to further boost its presence within the (healthcare) information-technology space.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is fda action or product recalls on implanted and surgical devices.
med
device safety and recall risk
When you sell implants and surgical tools, trust is the product as much as the hardware. A safety notice, recall, or lawsuit can move faster than any sales team can fix.
impact: this risk can pressure the full $25.1B revenue base because hospital trust does not fail in neat segments.
med
procedure-volume slowdown
Healthy elective procedures and hospital spending helped support recent results. If those volumes cool, Stryker feels it directly.
impact: the stock trades at 26.3x earnings because investors expect steady demand. Slower procedures would hit both growth and the multiple.
med
acquisition integration risk
More than 60 acquisitions in a decade built scale. It also creates constant integration work across products, sales teams, and systems.
impact: with $14.8B in long-term debt already on the balance sheet, more dealmaking only works if the returns stay disciplined.
med
premium-multiple risk
This is a high-quality company. The market knows that. Three-year returns still trailed the index by $210 on a $10,000 start because paying up for quality still matters.
impact: if growth slips from the recent 11.2% pace, a 26.3x earnings multiple gives the stock room to compress.
a recall would hurt fast, but the quieter risk is simpler: if a company priced for consistency stops looking consistent, the valuation usually corrects before the fundamentals do.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next earnings guide
The stock is priced for another clean year. Watch whether management keeps the steady-growth script intact after FY2026 opens.
trend
procedure volume
Healthy surgery counts are doing real work here. If elective procedures cool, revenue growth will usually tell you quickly.
risk
recalls and safety notices
One product issue can ripple across hospital purchasing decisions. This is the risk that can change the story fastest.
metric
deal cadence
With more than 60 acquisitions in a decade, new deals are not side notes. They are part of how Stryker extends its reach.
Analyst rankings
short-term outlook
average
momentum score 3. in human-speak, analysts see a steady compounder here, not an obvious short-term breakout.
risk profile
above average
stability score 2 — safer than roughly 80% of stocks. For a device maker, that is sturdy.
chart momentum
average
technical score 3 — the chart is acting normal. No panic, no melt-up.
earnings predictability
95 / 100
this is the ranking that matters most. Management tends to deliver numbers close to what investors expect.
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 1,019 buyers vs. 893 sellers in 3q2025. total institutional holdings: 0.3B shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$310
$583
$357
current price
$447
target midpoint · +25% from current · 3-5yr high: $665 (+85% · 18% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive